Fusilev Sales to Fall Sharply
Spectrum Pharmaceuticals predicted it will bring in no more than $90 million selling its Fusilev cancer drug this year. That's a huge drop from 2012's $204 million, and the stock is getting hammered. SPPI drops 35 percent before the bell on my tradeMONSTER platform.
Velti Earnings, Revenue Miss
Velti, which provides mobile marketing technology, earned $0.39 a share in the fourth quarter on revenue of $97.5 million. Analysts had expected $0.59 and $106.9 million, respectively. VELT drops 28 percent in the premarket
ASM Divestiture Leaves Bitter Taste
ASM International said it plans to divest its stake in ASM Pacific Technology, but Bloomberg is reporting that it will result in maximum proceeds of $567 million. Investors had hoped for more, and ASMI is down 13 percent in early trading.
More From optionMONSTER